The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) September 26, 2022
✳️ 10 tweet #NephJC catch-up ✳️
Did you ever think of using acetazolamide for acute congestive heart failure?
Read on to see whether we should or we should not! pic.twitter.com/e6XHi1JouG